Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration (AMD)

F. Ryan Prall, MD


October 15, 2020

Treatment guidelines recommend antiangiogenic agents that block or neutralize vascular endothelial growth factor (VEGF) as first-line therapy for wet AMD. Adjunctive therapies are also available.

Ranibizumab and aflibercept are approved anti-VEGF drugs. Bevacizumab, another VEGF inhibitor, is approved to treat several cancers but is not currently approved by regulatory bodies to treat AMD. Bevacizumab is often prescribed for off-label use, in part because of its efficacy, effectiveness, and favorable cost profile.

PDT may offer the chance to help the subset of patients who experience disappointing visual outcomes with antiangiogenics alone. However, studies have shown that monotherapy with anti-VEGF agents may be at least as effective as combination treatment with PDT, and guidelines state that PDT alone should not be offered to patients with active wet AMD.

Learn more about approved treatments and experimental approaches to improving management of wet AMD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: